CVRx (NASDAQ:CVRX) Rating Lowered to “Hold” at Canaccord Genuity Group

CVRx (NASDAQ:CVRX) was downgraded by analysts at Canaccord Genuity Group from a “buy” rating to a “hold” rating in a report issued on Friday, MarketBeat Ratings reports. They presently have a $2.00 target price on the stock, down from their prior target price of $5.00. Canaccord Genuity Group‘s price target suggests a potential upside of 130.23% from the stock’s current price.

CVRX has been the topic of a number of other research reports. Wall Street Zen raised CVRx from a “sell” rating to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a research report on Friday, October 30th. William Blair lowered CVRx from an “outperform” rating to a “market perform” rating in a research note on Friday. Cantor Fitzgerald reduced their target price on CVRx from $13.00 to $5.00 and set an “overweight” rating on the stock in a research report on Monday, August 17th. Finally, Lake Street Capital cut CVRx from a “buy” rating to a “hold” rating and lowered their price target for the company from $14.00 to $3.50 in a report on Friday, August 7th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.70.

CVRx Stock Performance

NASDAQ:CVRX opened at $0.87 on Friday. The company has a debt-to-equity ratio of 2.94, a current ratio of 8.04 and a quick ratio of 6.87. The firm has a market cap of $23.14 million, a PE ratio of -0.43 and a beta of 0.81. The firm has a 50 day simple moving average of $2.08 and a 200-day simple moving average of $5.16. CVRx has a 1-year low of $0.77 and a 1-year high of $10.28.

CVRx (NASDAQ:CVRX) last announced its earnings results on Thursday, November 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The firm had revenue of $13.83 million for the quarter, compared to analyst estimates of $13.93 million. CVRx had a negative return on equity of 180.78% and a negative net margin of 88.28%. On average, equities analysts expect that CVRx will post -2.00 EPS for the current year.

Insider Buying and Selling at CVRx

In related news, COO Brent Binkowski purchased 26,223 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were bought at an average price of $2.91 per share, for a total transaction of $76,308.93. Following the acquisition, the chief operating officer directly owned 56,514 shares in the company, valued at $164,455.74. This trade represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 16.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Johnson & Johnson acquired a new position in CVRx in the second quarter valued at $20,687,786. Royal Bank of Canada increased its stake in CVRx by 6,559.3% during the first quarter. Royal Bank of Canada now owns 706,950 shares of the company’s stock worth $6,688,000 after acquiring an additional 696,334 shares during the last quarter. BlackRock Inc. acquired a new stake in CVRx during the second quarter worth about $6,402,000. FourWorld Capital Management LLC increased its stake in CVRx by 28.9% during the first quarter. FourWorld Capital Management LLC now owns 231,996 shares of the company’s stock worth $2,195,000 after acquiring an additional 51,996 shares during the last quarter. Finally, Quantinno Capital Management LP raised its holdings in shares of CVRx by 52.4% in the 1st quarter. Quantinno Capital Management LP now owns 115,818 shares of the company’s stock worth $1,096,000 after purchasing an additional 39,845 shares during the period. 75.27% of the stock is owned by hedge funds and other institutional investors.

More CVRx News

Here are the key news stories impacting CVRx this week:

• Neutral Sentiment: Trading in CVRx was temporarily paused under a Limit Up-Limit Down (LULD) volatility mechanism. The halt signals unusually volatile trading but does not, by itself, explain the move. Trading halt notice
• Negative Sentiment: CVRx reported Q3 revenue of $13.83 million, below the roughly $13.93 million analyst expectation, and a loss of $0.52 per share versus estimates of about $0.50. Revenue declined year over year, and the company lowered its FY2026 outlook, raising concerns about growth and execution. CVRx reports Q3 revenue decline and lowers outlook
• Negative Sentiment: Canaccord Genuity cut its rating from Buy to Hold and reduced its price target from $5 to $2. William Blair also downgraded the stock, moving from Outperform to Market Perform. The lowered ratings and targets add pressure despite the $2 target remaining above the recent share price. William Blair downgrade

CVRx Company Profile

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.